ArticleMolecular therapy. Oncology2025
Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma (SS) is an aggressive mesenchymal malignancy that is refractory to treatment with immune checkpoint inhibitor-based therapy. We investigated the infiltrating T cell immune status in archived patient samples and tested the efficacy of an oncolytic measles virus (MV) encoding the secretory form of the neutrophil-activating protein (s-NAP) in SS. To assess T cell infiltration, we performed T cell receptor (TCR) sequencing on archived formalin-fixed, paraffin-embedded specimens, comparing SS with undifferentiated pleomorphic sarcoma (UPS), a highly immunogenic sarcoma. Patients with SS had significantly lower T cell infiltration, reduced clonality, and higher TCR diversity than those with UPS. No differences were observed in the T cell repertoire between monophasic and biphasic SS or between primary and metastatic SS samples. Oncolytic MV-s-NAP infection of validated monophasic and biphasic SS cell lines demonstrated dose-dependent killing in all cell lines tested and a significant increase in proinflammatory markers compared to untreated controls. Additionally, repeated intratumoral injections of MV-s-NAP in an SYO-1 SS xenograft model demonstrated significant anti-tumor effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.